FDA approves warfarin labeling change

Aug 16, 2007

The U.S. Food and Drug Administration has approved a labeling change for the widely used blood-thinning drug Coumadin (warfarin).

The Bristol-Myers Squibb Co. of Princeton, N.J., the manufacturer of Coumadin -- as well as manufacturers of warfarin, the generic version of the drug -- will add information to labels explaining a person's genetic makeup might influence how they respond to the drug. Research has shown a person's response to warfarin depends on variants of the genes CYP2C9 and VKORC1.

The FDA said the labeling change highlights the opportunity for healthcare providers to use genetic tests to improve their initial estimate of what is a reasonable warfarin dose for individual patients.

It's estimated about 2 million people start taking warfarin in the United States every year to prevent blood clots, heart attacks and stroke. Warfarin is a difficult drug to use because people taking a dose larger than they can tolerate are at risk of life-threatening bleeding. Those who receive too low a dose are at risk of equally dangerous blood clots.

Warfarin is the second most common drug -- after insulin --implicated in U.S. emergency room visits for adverse drug events.

Copyright 2007 by United Press International

Explore further: Prevnar, Pfizer's pneumonia vaccine, okayed for adults in EU

add to favorites email to friend print save as pdf

Related Stories

IOC defends Rio legacy amid green protests

2 hours ago

Ecological protests on Saturday dogged the final day of an International Olympic Committee executive board meeting in Rio as green campaigners slated the choice of a nature reserve to hold the golf event ...

Japan's NTT to buy German data centre operator

2 hours ago

Japanese telecom giant NTT Communications is looking to acquire German data centre operator e-shelter, as it seeks to cash in on growing demand in Europe, a newspaper reported Saturday.

Fashionable or geeky—the modern watch dilemma

6 hours ago

It's Milan fashion week, you've got tickets to the catwalk shows and an outfit to die for, but which watch to wear? A chunky smartwatch or chic ticker that can't tell the time?

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

13 hours ago

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

16 hours ago

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.